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TO THE EDITOR
The skin fragility disorder, recessive
dystrophic epidermolysis bullosa (RDEB)
results from mutations in COL7A1, lead-
ing to reduced or absent type VII
collagen (C7) and defective anchoring
ﬁbrils at the dermal–epidermal junction
(Fine et al., 2014). Currently, there is no
cure, and most individuals develop life-
shortening squamous cell carcinomas
(Fine and Mellerio, 2009). RDEB also
has a major health economic burden;
wound dressings for a 10-year-old child
can cost $680 per day (Kirkorian et al.,
2014), which equates to 4$250,000
annually.
Reported clinical trials of cell-based
therapies for RDEB comprise intrader-
mal allogeneic ﬁbroblasts (Petrof et al.,
2013; Venugopal et al., 2013), bone
marrow transplantation (Wagner et al.,
2010), intradermal bone marrow–
derived mesenchymal stromal cells
(BM-MSCs) (Conget et al., 2010), and
intravenous BM-MSCs in RDEB adults
(El-Darouti et al., 2013; abstract
only). Ex vivo COL7A1 keratinocyte
gene therapy is also being evaluated
(Siprashvili et al., 2014).
MSCs are heterogeneous cells that
undergo self-renewal or differentiate
into mesenchymal lineages (Caplan,
1991). MSCs also have non-progenitor
functions in immune regulation, cell
growth, and tissue repair (Phinney and
Prockop, 2007; Chen et al., 2008).
Nevertheless, healing is not associated
with large numbers of therapeutic
MSCs in injured tissues, suggesting that
paracrine beneﬁts may modulate
inﬂammatory and immune responses
(Baraniak and McDevitt, 2010). Our
interest focuses on the potential of
intravenous allogeneic BM-MSCs to
help people living with RDEB.
Ten children were included in the
clinical trial and are detailed in Supple-
mentary Table S1 online, with the
trial protocol shown in Supplementary
Figure S1 online. The trial was approved
by the UK Medicines and Healthcare
Products Regulatory Agency, with
EudraCT number: 2012-001394-87; the
UK National Research Ethics Committee
London-Bloomsbury provided ethics
approval (Ref:12/LO/1258), and the trial
was registered prospectively with www.
controlled-trials.com ISRCTN46615946.
Written informed consent was obtained
for each subject. Inclusion/exclusion cri-
teria are presented in Supplementary
Table S2 online, and study interventions
are listed in Supplementary Table S3
online. Details of the BM-MSCs are pro-
vided in Supplementary Table S4 online.
Each participant received three intrave-
nous infusions of BM-MSCs (day 0, 7, and
28; each dose 1–3×106 cells kg–1) with
no HLA matching or pre-conditioning.
With regard to safety, there were 163
adverse events (AEs; Supplementary
Tables S5–S7 online). Initially, two
serious AEs, esophageal dilatation and
skin infection, were reported but were
subsequently downgraded (protocol
version 4.0, 1 August 2014), as they
were considered to be complications
of RDEB and not the cells. Indeed,
127/163 (78%) of AEs were either
unlikely or not related to the BM-MSCs.
Concerning the severity of MSC-
related AEs, there were two severe events
of DMSO odor, although odor was noted
following 28/30 infusions (lasting up to
48 hours). Mild nausea occurred during
two infusions, and abdominal pain and
bradycardia were observed during two
other infusions; all resolved within 15
minutes without treatment or hemody-
namic compromise. No AEs resulted in
discontinuation of MSCs.
Laboratory assessments did not reveal
any adverse impact of the BM-MSCs on
renal, liver, or bone marrow function.
Anti-C7 antibodies were detected by
ELISA at baseline in 9/10 participants,
but no sera bound to the dermal–epider-
mal junction by indirect immunoﬂuores-
cence microscopy. Following MSCs, there
were no changes in ELISA or indirect
immunoﬂuorescence microscopy data
(Supplementary Table S8 online).
Collectively, the tolerance data
appear encouraging, although it should
be noted that a zero event rate for a
serious AE in just 10 patients is compa-
tible with an upper 95% conﬁdence
interval of over 30%.
With regard to secondary outcome
measures, the data are summarized in
Supplementary Table S9 online. Skin
biopsies revealed no increase in C7
and no new anchoring ﬁbrils at day 60.
Fluorescence in situ hybridization analy-
sis did not show donor-cell chimerism.
Birmingham epidermolysis bullosa
severity score (BEBSS) and global severity
score questionnaires were completed for
all the 10 participants (Supplementary
Figures S2 and S3 online). Mean parent-
reported pain score was lower at 60 days
than at baseline (mean difference: −5.5
points; 95% conﬁdence interval (CI):
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−16.3, 5.3); similar changes were
seen at day 180 (mean difference −3.0
(−14.7, 8.7) (Supplementary Figure S4
online). Change in mean disease severity
(total BEBSS) was −5.2 points (95% CI:
−10.7, 0.3), and change in mean BEBSS
total body surface area (TBSA%) was –
5.9 points from baseline to day 60
(−15.3, 3.5); similar changes were seen
at 180 days for both BEBSS measures
(Supplementary Figure S5 online). Mean
global severity score was 7.0 at baseline
and 4.6 at day 60 (mean difference: −2.4
(95% CI: −3.4, −1.4). Corresponding
mean change at day 180 was −1.6
(−3.0, −0.24). Mean quality of life score
(higher is worse) reported by parents was
41.9 at baseline and 37.5 at day 60
(mean difference: −4.4; 95% CI: −8.1,
−0.7) and 39.0 at day 180 (mean
difference: −2.9; 95% CI: −7.5, 1.8)
(Supplementary Figure S6 online).
Qualitative data (telephone interviews
at 9 months) revealed impressions for
better wound healing in all the 10
subjects and for less skin redness in 9/10
with clinical beneﬁts lasting for ~4–
6 months (Figure 1 and Supplementary
Figures S7 and S8 online). These data are
presented in Supplementary Tables S10
and S11 online. Median blister counts at
baseline, day 60, and 180 were 5.5, 3.5,
and 3.5, respectively (Supplementary
Figure S9 online). Mean suction blister
times were limited to just two time points:
10.2 at baseline and 11.9 at day 100
(mean difference: 1.7; 95% CI: −0.5, 3.9);
individual data are shown in Figure 2.
Overall, the changes in efﬁcacy out-
comes were promising, although it
should be remembered that this is an
unblinded study of participants who are
keen to help, thus giving a potential for
positive information bias.
Many of the subjective verbatim inter-
views, however, disclosed perceived
beneﬁts, such as better sleep (child and
parents), a parent being able to return to
work part-time because of reduced
caring needs, and a family being able
to plan their ﬁrst vacation together and
so on. Thus, although further studies of
BM-MSCs in RDEB are needed to
demonstrate efﬁcacy, address mechan-
isms of action, and determine optimal
cell dosage, our current ﬁndings indicate
some beneﬁts for daily life.
Practically, MSCs can be given as a
bolus over 10minutes without sedation,
and the child can resume normal activ-
ities within 1 hour. If MSCs were given in
the clinic at the doses used in this trial,
repeated every 6 months, we estimate
that the costs would be similar to current
biologics licensed to treat patients with
chronic inﬂammatory diseases but with
the potential for cost-neutrality or sav-
ings based on reduced dressing needs
and shortened carer time.
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Before
After
Figure 1. Improved wound healing and reduced skin erythema 8 weeks after the third infusion of bone
marrow–derived mesenchymal stromal cells in subject I.
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Figure 2. Suction blister times for each subject at baseline (day −120) and 100 days after the infusions
of bone marrow–derived mesenchymal stromal cells.
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TO THE EDITOR
Skin lesions in myelodysplastic syn-
drome (MDS) include neutrophilic
dermatoses (Vignon-Pennamen et al.,
2006), leucocytoclastic vasculitis,
infections, drug reactions, and leukemia
cutis (Avivi et al., 1999). In MDS patients,
leukemia cutis, a blastic myeloid cell
inﬁltration of the skin (Cho-Vega et al.,
2008), has a poor prognosis (Aractingi
et al., 1995; Kaddu et al., 1999), with a
rapid development of acute myeloid
leukemia (AML) and death (Longacre
et al., 1993). The prognostic value of
skin lesions inﬁltrated only by non-
blastic MDS tumor cells has not yet
been characterized.
We studied 24 MDS patients with
non-blastic skin inﬁltrate and compared
them with 20 leukemia cutis patients.
This study adheres to the declaration of
Helsinki principles, and patient consent
for experimentals was not required
because the French laws consider human
tissue left over from surgery as discarded
material. Detailed patient data are given
in Supplementary Table S1 online.
Between 1995 and 2012, 800
patients were diagnosed with MDS in
Hôpital-Saint-Louis, Paris. One hundred
and ﬁfty patients underwent skin biopsy,
and we identiﬁed 24 skin involvements
by non-blastic tumor cells, deﬁned as
medium-sized immature myeloid cells
(Figure 1) with (i) abundant eosinophilic
cytoplasm and (ii) twisted nuclei or
pseudo-Pelger-Huet anomaly, a speci-
ﬁc myelodysplasia marker on blood
smears (Shetty et al., 2001). The tumor
cells had a combined myeloid and
monocytic phenotype, expressing
both myeloperoxydase (100% of
cases) and CD163 (100%) or CD68
(96%). They did not express CD34,
CD117, or CD56. The proliferative
index with Mib-1 was low (o10%
positive cells) in 56% of cases, or
intermediate (10 to 66% positive
cells) in 44% of cases, but never high
(≥66% positive cells). Mature neutro-
phils and normal CD3+ lymphocytes
were numerous (46% and 100% of
cases, respectively) and edema was
frequent (67%).Accepted article preview online 10 April 2015; published online 14 May 2015
Abbreviations: AML, acute myeloid leukemia; FISH, ﬂuorescent in situ hybridization; IPSS, International
Prognostic Scoring System; MDS, myelodysplastic syndrome; OS, overall survival
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